Read the article?

“We’re moving into the era of 50%, 60% percent efficacy. Reminds you of flu [vaccine], doesn’t it?” Monto said.

Link-Gelles agreed with the analogy, noting that in a good year, influenza vaccines offer protection in this range. “So this is kind of exactly where we would expect it to be for a vaccine for a respiratory virus in a population that has some underlying immunity to that virus.”